Entera Bio FY2025 net loss $11.4M, cash runway to mid-Q3 2026; EB613 Phase 3 submitted

Entera Bio Ltd.

Net loss $11.4M ($0.25/sh) vs $9.5M in FY2024; R&D expenses $6.0M up from $4.5M.
Cash $14.9M at Dec 31, 2025 incl. $7.8M restricted for OPKO collab; operating cash burn $7.4M.
EB613 Phase 3 protocol submitted Mar 2026; FDA feedback expected late Apr 2026 with topline in H2 2028.
EB612 (LA-PTH) collaboration with OPKO expanded; IND filing expected late 2026.
EB618 (oral OXM) PK/PD validation complete; Phase 1 initiation dependent on injectable data by YE 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Entera Bio Ltd. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 27, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the year ended December 31, 2025 and business updates.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-26-001792

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.